Materials or feedstock substitution Product design or reformulation Equipment or process modifications Spill or leak prevention On­site reuse, recycling or recovery Improved inventory management or purchasing techniques Good operator practice or training About us News Contact us Stay connected HEALTH healthycanadians.gc.ca TRAVEL travel.gc.ca SERVICE CANADA servicecanada.gc.ca JOBS jobbank.gc.ca ECONOMY actionplan.gc.ca Canada.gc.ca Terms and Conditions Transparency Version: 3.13.0 Identify at least one reason why no option to reduce the use or creation of this substance was implemented at your facility: Select the applicable reason or reasons ** There are no alternative processes and/or equipment identified, New equipment and/or processes were investigated, however, deemed unfeasible Explanation of the reasons why no option will be implemented   Rationale for why the listed options were chosen for implementation   General description of any actions undertaken by the owner and operator of the facility to reduce the use and creation of the toxic substance at the facility that are outside of the plan   License Number of the toxic substance reduction planner who made recommendations in the toxic substance reduction plan for this substance (format TSRPXXXX): * TSRP0123 Name of the toxic substance reduction planner who made recommendations in the toxic substance reduction plan for this substance (First Name Last Name) Daryl Chartrand License Number of the toxic substance reduction planner who has certified the toxic substance reduction plan for this substance (format TSRPXXXX): * TSRP0123 Name of the toxic substance reduction planner who has certified the toxic substance reduction plan for this substance (First Name Last Name) Daryl Chartrand What version of the plan is this summary based on?

These regulations prohibit discrimination against qualified individuals based on their status as protected veterans or individuals with disabilities, and prohibit discrimination against all individuals based on their race, color, religion, sex, national origin, sexual orientation or gender identity. 12.12 Both parties shall act in compliance with all applicable (inter)national privacy laws, rules, regulations and standards, including guidelines and decisions of the European Data Protection Board, in connection with the performance of the Agreement. Supplier, Supplier’s insurer(s) and anyone claiming by, through, under or on Supplier’s behalf shall have no claim, right of action or right of subrogation against Avient or its customers based on any loss or liability insured against under the Required Insurance.

Поммерлох, Люксем- бург 19 Route de Bastogne Pommerloch, Luxembourg, L-9638 Телефон: +352 269 050 35 Факс: +352 269 050 45 www.avient.com http://www.avient.com Краткий справочник: Что следует и не следует делать в рамках антимонопольной политики Контрольный список по соблюдению требований антимонопольного законодательства Защита от преследований Фиксация возможных нарушений Заключение Потенциальные проблемные области в сфере антимонопольного законодательства Нарушения антимонопольного законодательства Общий обзор Антимонопольного законодательства США Общие сведения о политике Горячая линия по вопросам этики компании Avient

Francisco Nakasato, 1700 13295-000 Itupeva Sao Paulo, Brazil 电话：+55 11 4593 9200 欧洲 地区总部，卢森堡 Pommerloch 19 Route de Bastogne Pommerloch, Luxembourg, L-9638 电话：+352 269 050 35 传真：+352 269 050 45 www.avient.com http://www.avient.com

Seller has based any recommendations to Buyer upon information that Seller considers reliable, but Seller makes no warranty as to any results Buyer might obtain in Buyer’s use(s) for the Product. Buyer must give Seller written notice of the existence of each claim involving Product (whether based on breach of contract, breach of warranty, negligence, strict liability, other tort or otherwise) within the earlier of thirty (30) days after receipt of the quantity of Product forming the basis for the claim or applicable shelf-life expiration, if any.

They are based on management’s expectations that involve a number of business risks and uncertainties, any of which could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. 15 2021 O U TLO O K A S P R O V I D E D O N F E B R U A R Y 9 , 2 0 2 1 W E B C A S T Synergies ($ millions) Initial Three-Year Estimate Revised Three-Year Estimate 2021 Expected Realization Administrative $ 18 $ 20 $ 15 Sourcing 24 30 15 Operational 18 25 5 Total Synergies $ 60 $ 75 $ 35 CLARIANT INTEGRATION & COST SYNERGIES UPDATE 17 • Integration going extremely well: synergy target increased from $60 million to $75 million • $5 million of synergies in 2020 and expect to realize $35 million in 2021 • Relentless focus on guiding principles of safety first, employee collaboration and exceeding customer expectations • Future revenue synergies are not part of these estimates and represent additional growth over the long term $86 $103 $0.53 $0.70 ORGANIC GROWTH PROJECTIONS – Q1 18 Sales Adjusted Operating Income $991 $1,090 + 10% Adjusted EPS + 20% + 32% (in millions) (in millions) (1) (1) (1) (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition $308 $360 $1.93 $2.40 ORGANIC GROWTH PROJECTIONS – FULL YEAR 19 Sales Adjusted Operating Income $3,783 $4,100 + 8% Adjusted EPS + 17% + 24% (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition (in millions) (in millions) 2020 Pro forma $3,783 $308 Sustainable Solutions 60 11% 24 Healthcare 60 11% 18 Composites 20 10% 10 Growth in Emerging Regions 50 7% 11 Other (GDP growth) 82 5% 11 Sub-total $4,055 7% $382 COVID Response Applications (25) - (11) Outdoor High Performance Applications (15) - (7) Asia Payroll Tax Subsidy (COVID) - - (4) FX Impact 85 - 7 Synergies - - 30 Incentives, Travel, Other Employee Costs - - (37) 2021 Estimated $4,100 8% $360 2021 ORGANIC SALES AND OPERATING INCOME 20 (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition (2) COVID Response Applications: facemasks, personal protective equipment Sales Growth Rate Adjusted Operating Income$ millions (2) CASH FLOW AND LEVERAGE 21 • Asset light business generates significant free cash flow • Cash generation in 2021 partially offset by restructuring activities to capture synergies associated with the Clariant Masterbatch acquisition • Cash flow deployed to M&A, opportunistic share repurchases and balance sheet / leverage reduction 3.5x 2.7x 2.1x 2019PF 2020PF 2021E Net Debt / Adjusted EBITDA (1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition ($ millions) 2020 2021E Adjusted EBITDA 382 510 Working Capital: Source / (Use) 116 (30) Cash Taxes (40) (53) Interest Paid (67) (76) CapEx (62) (75) CapEx for Synergy Capture (2) (20) Restructuring for Synergy Capture (11) (25) Other 22 19 Free Cash Flow 338 250 22 • 8% increase in sales drives 24% increase in adjusted EPS to $2.40 ($2.70 excluding step-up depreciation and amortization) as a result of continued growth in sustainable solutions and synergy capture • Clariant synergy capture ahead of schedule: $35M of savings planned from Clariant Masterbatch acquisition • Adjusted EBITDA of $510M – highest level in company history • Deleveraging ahead of schedule – 2.1x net debt to adjusted EBITDA by the end of 2021 2021 PROJECTIONS PEER COMPARISONS 23 As a specialty formulator, we don’t require significant capital investment, as compared to the base resin raw material suppliers we purchase from.

They are based on management’s expectations that involve a number of business risks and uncertainties, any of which could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. Senior management believes the measures described above are useful to investors because they allow for comparison to Avient's performance in prior periods without the effect of items that, by their nature, tend to obscure Avient's operating results due to the potential variability across periods based on timing, frequency and magnitude.

It is based on three principles: • Design out waste and pollution • Keep products and materials in use • Regenerate natural systems By following these principles, a circular economy can drastically reduce waste, pollution, and resource depletion.

MATERIAL DESCRIPTION BASE RESIN Trilliant™ HC2020 Copolyester Trilliant™ HC8910/8920 Polyketone/ABS blend Trilliant™ HC2120 Tritan Trilliant™ HC3120 PC Trilliant™ HC5210 PP Trilliant™ HC6010 PA6 Trilliant™ HC6610 PA66 Trilliant™ GRV-NP-110-W PA12 TRILLIANT™ HC THERMOPLASTICS • Chemically resistant replacement for FR PC/ABS, FR PC/PET & FR COPE, providing UL 94 Yellow Card V-0 flame rating at 1.5 mm, V-1 at 0.75 mm thicknesses for a broad color spectrum • Outperforms PC/ABS, PC/PET and COPE in resistance to common disinfectants • Retains tensile strength after 72-hour exposure to common hospital disinfectants, and shows better long-term chemical resistance as compared to PC blends and COPE • Exhibits good impact and temperature resistance • Available in natural grades, standard medical colors, or custom pre-colored products • Medical device housings • MRI, X-ray, CT scanner components • Surgical instruments such as staplers, dissectors, scissors • Auto-injector pen TRILLIANT™ HC ELECTRICALLY CONDUCTIVE FORMULATIONS • Consistent conductivity ensures repeatable part performance and minimizes failures related to inconsistent electrical conductivity • High flow and easy processing facilitate filling of thin wall parts and multiple cavity tools, which enable faster cycle times and lower per-unit part costs • Superior durability reduces breakage and resultant scrap related costs • Less tendency to flash results in improved appearance and less fluid retention in or on the tip, thus driving greater accuracy and less potential for cross-contamination • High strength produces parts with greater stiffness and warp resistance, again minimizing scrap-related costs • Conductive pipette tips TEST TEMS SPECIFIC GRAVITY MELT FLOW RATE (230OC, 2.16KG) TENSILE FLEXURAL FLEXURAL MODULUS IMPACT STRENGTH NOTCHED, IZOD SURFACE RESISTIVITY Method ASTM D-792 ASTM D-1238 ASTM D-638 ASTM D-790 ASTM D-790 ASTM D-256 ASTM D-257 Unit -- g/10min MPa MPa MPa J/m Ohms/sq.

The Audit Committee, after consultation with management, the independent auditor and others as the committee deems appropriate, shall make the final decision to restate previously issued financial statements, if necessary, because of an error in such financial statements as addressed in Accounting Principles Board Opinion No. 20 (APB Opinion No 20) or shall make the decision to disclose or take actions to prevent future reliance on a previously issued audit report or completed interim review related to previously issued financial statements based upon notification or advisement by its independent auditor.